70 Talks Being Presented for the First Time or Featuring New Data

CYT101, a High-Affinity IL-15Rbg Agonist, Induces Safe and Potent Anti-Tumor Immune Activities in Patients with Solid Tumors and Supports Further Clinical Investigations
Irena Adkins, PhD, Science Lead, Pharmacology, SOTIO as

Predicting Antibody Developability through Experimental and in silico Approaches
Marc Bailly, PhD, Principal Scientist, Merck Research Labs

Efficient Production of Recombinant Secretory IgA against Clostridium Difficile Toxins in CHO-K1 Cells
Anton Bauer, PhD, MBA, Medical University of Vienna

PD-1 Antibodies as Precision Medicine Informed Mono- and Combination Therapies Are Transforming Cancer Care
Roy Baynes, MD, PhD, Senior Vice President & Head, Global Clinical Development; CMO, Merck, Sharp and Dohme

Antibody-Targeted Lipid-Nanoparticle Mediated Inhibition of the GPCR RXFP1 Signaling Pathway as a Therapeutic Approach for Ovarian Cancer
Itai Benhar, PhD, Professor, Biomedicine & Cancer Research, Tel Aviv University

Application of Molecular Dynamics Simulations for Developability Assessment and Formulation Development of Biologics
Carolin Berner, Chair of Pharmaceutical Technology & Biopharmaceutics, Pharmaceutics, University of Munich

iMAM: A High-Resolution LC-MS Intact Mass Analysis Multi-Attribute Method Workflow

Jonathan Bones, PhD, Principal Investigator, Characterisation and Comparability Laboratory, National Institute for Bioprocessing Research and Training (NIBRT)

Targeting of Tumor-Specific Peptide Antigens with Bispecific T Cell-Engaging Receptor (TCER) Molecules
Sebastian Bunk, PhD, Senior Director, Immatics

Accelerated Predictive Stability for Biologicals and Vaccines
Didier Clenet, Senior Scientist, Formulation & Stability & Bioprocess R&D, Sanofi Pasteur

Using Computational Structural Modelling to Identify the Precise Epitopes of Coronavirus-Binding Antibodies

Charlotte M. Deane, PhD, Professor of Structural Bioinformatics, Statistics, University of Oxford

Optimizing the High-Yield Production of SARS-CoV-2 Proteins for Large-Scale Deployment of Serology Assays
Dominic Esposito, PhD, Director, Protein Sciences, Frederick National Laboratory

Expression of a Pathogenic Virulence Factor Enhances the Efficacy of CAR-T Cell Therapy Against Solid Tumors
Magnus Essand, PhD, Co-Founder, Elicera Therapeutics; Prof, Immunology, Genetics and Pathology, Uppsala University

Antibody CDR Design Using High-Capacity Machine Learning
Stefan Ewert, PhD, Senior Investigator, Biologics Center, Novartis Institutes for Biomedical Research

Beehive Hexagonal Structures for Agonism and Antagonism – The TNFR2 Paradigm
Denise L. Faustman, MD, PhD, Associate Professor & Director, Immunobiology Labs, Massachusetts General Hospital

Preclinical Development of NI-1801, a MSLN/CD47 Bispecific Antibody
Nicolas Fischer, PhD, CEO, Light Chain Bioscience

A First in Class Anti-TNFR2 Ab (BI-1808) for Single Agent and Anti-PD-1 Combination Immunotherapy of Cancer

Björn L. Frendeus, PhD, CSO, BioInvent International AB

A Compact Vocabulary of Paratope-Epitope Interactions Enables Predictability of Antibody-Antigen Binding
Victor Greiff, PhD, Associate Professor, Immunology, University of Oslo, Norway

Targeting Perivascular Macrophage Tumor Vasculature Interactions to Restore an Immune-Competent Tumor Microenvironment
René M.A., Hoet, PhD, CSO, Montis Biosciences BV

A Novel Tumor Selective Anti-CD137 Agonist Antibody Activated by Elevated Extracellular ATP in Tumor Microenvironment
Yuji Hori, PhD, Research Scientist, Discovery Biological, Chugai Pharmaceutical Co. Ltd.

Development of Multispecific Assemblies of Nanofitins with Anti-Tumor Activities
Perrine Jacquot, Junior Project Manager, Affilogic

mRNA-Based COVID-19 Vaccines: Structure, Formulation and Stability

Wim Jiskoot, PhD, Professor, Drug Delivery Technology, Leiden University

Development of a High-Throughput cIEF Method for Quantification of Full and Empty Viral Particles for Cell and Gene Therapies
Jenifer Kaplan, PhD, Principal Scientist I, Novartis Institutes for Biomedical Research

Finding the Needle in the Haystack – A New Method for Selecting High-Producing Stable Cells

Dennis Karthaus, MSc, Director, Protein Products & Assays, IBA Lifesciences

Engineered Glutathione S-Transferase Tag Suitable for High-Yield Soluble Expression at Low Temperature

Takanori Kigawa, PhD, Team Leader, Laboratory for Cellular Structural Biology, RIKEN Center for Biosystems Dynamics Research

Engineering Antibodies for Next-Generation Cancer Immunotherapy
Christian Klein, PhD, Cancer Immunotherapy Discovery, Roche Innovation Center Zurich, Roche Pharma Research & Early Development, pRED

Selecting the Right Antibody Using Complex Phage Selections and NGS
Peter Kristensen, PhD, Associate Professor & Head of Biotechnology, Chemistry & Bioscience, Aalborg University

A Pivotal Role for Concurrent Chemotherapy and γδ T Cell Therapy (Drug Resistant Immunotherapy - DRI) in the Post Induction Primary Disease Setting for Reducing the Immunosuppressive Properties of the Tumor Microenvironment
Lawrence Lamb, Jr., PhD, Executive Vice President & CSO, Incysus Therapeutics, Inc.

CHO Cell Line Development and Engineering via Site-Specific Integration: Challenges and Opportunities
Jae Seong Lee, PhD, Assistant Professor, Applied Chemistry & Biological Engineering, Ajou University

Extending the Half-Life of IgA as Therapeutic Antibody through Albumin
Jeanette H.W. Leusen, PhD, Associate Professor, Translational Immunology, Utrecht University

Development of an Anion Exchange Chromatography Assay for Determining Empty and Full AAV Capsid Content in AAV6.2
Thomas Linke, Senior Scientist, Process Development, AstraZeneca

ICT01: A First-in-Class Clinical Stage Anti-BTN3A Antibody with the Capacity to Harness the Vg9/Vd2 T Cells in Cancer
Loui Madakamutil, PhD, CSO, ImCheck Therapeutics

Antibody Discovery, Affinity Maturation and Developability Screening from Large Mammalian Display Libraries
John D. McCafferty, PhD, CEO & Founder, IONTAS and CEO and Founder, Maxion Therapeutics

NKT Cells as a Platform for Redirected Cancer Immunotherapy
Leonid S. Metelitsa, MD, PhD, Professor, Pediatrics & Oncology, Baylor College of Medicine

Deep Neural Networks in Protein Engineering – From Predicting Stabilizing Sequences to Refining 3D Structures
Abhishek Mukhopadhyay, PhD, Principal Scientist and Group Lead, Molecular Simulations, Zymeworks, Inc.

Next-Generation Antibody-Cytokine Fusions for Cancer Therapy
Dario Neri, PhD, Full Professor, Chemistry & Applied Biosciences, ETH Zurich

To Sub 10 pM Affinity and Beyond! Discovery of a Next-Generation Highly Potent Long-Acting Anti IL-5 Antibody
Martin A. Orecchia, PhD, Team Leader, Antibody Discovery, GlaxoSmithKline

Preclinical Pharmacokinetics, Pharmacodynamics and Safety of RO7297089, a Novel Anti-BCMA/CD16a Bispecific Antibody for the Treatment of Multiple Myeloma
Ayse Meric Ovacik, PhD, Scientist, Developmental Sciences, Genentech, Inc.

Shifting from T to NK Immunotherapy
Aviad Pato, PhD, Head Research, Natural Killer Cells, Gamida Cell Ltd.

Targeting Glycan-Mediated Immune Regulation in Cancer and Inflammatory Diseases

Li Peng, PhD, Senior Vice President, Research & Early Product Development, Palleon Pharmaceuticals

Boltbody Immune Stimulating Antibody Conjugates (ISACs): From Preclinical to Clinical Research
Edith A. Perez, MD, CMO, Bolt Biotherapeutics, Inc.

Analytical Ultracentrifugation: An Auxiliary Tool for Vector Characterization
Robert Pletzenauer, Head of Process Analytics, Gene Therapy, Process Development, Takeda

The SHREAD Platform: SHielded, REtargeted ADenovirus for Paracrine Delivery of Therapeutics
Andreas G. Plueckthun, PhD, Professor & Head, Biochemistry, University of Zurich

Characterization of Adeno-Associated Virus-Based Gene Therapy Products by Mass Spectrometry
Yi Pu, PhD, Scientist II, Analytical Development, Biogen

Advancing Mass Spectrometry Technology in cGMP Environments
Da Ren, PhD, Scientific Director, Process Development, Amgen Inc.

Downstream Process of Adeno-Associated Viruses (AAV) – Purification, Characterisation and Formulation
Ruth Rieser, PhD Student, Pharmacy, Ludwig Maximilians University

Enhancing the Prefusion Conformational Stability of SARS-CoV-2 Spike Protein through Structure-Guided Design
Timothy Riley, PhD, Scientist, Amgen Inc.

Next-Generation CAR T Cells in the Clinic

Claire Roddie, PhD, Researcher, CAR T Cell Program, University College London

Characterization and Monitoring of Cell Therapy Attributes Using Mass Spectrometry
Richard Rogers, PhD, Associate Director, Bristol-Myers Squibb

A Valuable Alternative to Mammalian Systems: Baculovirus-Free Antigen and Antibody Expression in Insect Cells
Maren Schubert, Technical University of Braunschweig

Is There Safe Storage Temperature for Frozen and Freeze-Dried Biologicals?

Evgenyi Y. Shalaev, PhD, Research Investigator, Pharmaceutical Development, Abbvie, Inc.

Multimeric IgM Antibodies Targeting DR5 are Potent and Rapid Inducers of Tumor Cell Apoptosis in vitro and in vivo
Angus M. Sinclair, PhD, Vice President, Immuno-oncology Research, IGM Biosciences

Targeting the Immune Inhibitory Receptor LILRB4 to Treat Acute Myeloid Leukemia
An Song, PhD, CSO, Immune Onc Therapeutics Inc.

Third-Generation Methods of Antibody Discovery and Optimisation: In silico Rational Design
Pietro Sormanni, PhD, Royal Society University Research Fellow, Yusuf Hamied Department of Chemistry, University of Cambridge

Integrating Synthetic Biology and Computer-Aided Design to Advance Mammalian Bioproduction

Raja Srinivas, PhD, Co-Founder, Asimov, Inc.

Ultra-Dilute Solution Measurements of Antibody Self-Association
Charles G. Starr, PhD, Scientist, Developability & Preformulation Sciences, Sanofi Group

Combinatorial Targeting of Multiple Myeloma by Complementing T Cell Engaging Antibody Fragments
Gernot Stuhler, MD, Senior Physician & Group Leader, Hematology & Oncology & Medical Clinic II, University Hospital Wuerzburg

Not Grams and Not Even Milligrams Per Liter: Strategies for Homeopathic Protein Production
Sabine Suppmann, PhD, Head, Recombinant Protein Production, Max Planck Institute of Biochemistry

Rational Screening of Compatible Monoclonal Antibodies for Development as Fixed-Dose Combinations

Hristo Svilenov, PhD, Researcher, Technical University Munich, Germany

Maximizing the Therapeutic Potential of Allogeneic Natural Killer Cells

Joanne B.L. Tan, PhD, Director, Translational Biology, Nkarta Inc.

NMR Tools for the Assessment of Antibody-Drug Candidates Aggregation State
Pablo Trigo Mourino, PhD, Senior Scientist, Analytical Research & Development, MSD

FAP-CD40, a Novel Tumor-Stroma Targeted CD40 Agonist, Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Anti-Tumor Immunity
Christine Trumpfheller, PhD, Senior Scientist, Roche Innovation Center Zurich

Augmented Antibody-Based Anticancer Therapeutics Boost Neutrophil Cytotoxicity
Marjolein van Egmond, PhD, Professor, Oncology and Inflammation, Amsterdam UMC, The Netherlands

Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Éric Vivier, DVM, PhD, CSO, Innate Pharma

Targeted Immune Cell Activation by Systemic Delivery of Toll-Like Receptor 9 Agonist Antibody Conjugates Induce Potent Anti-Tumor Immunity
Hong I. Wan, PhD, President, CEO and Co-Founder, Tallac Therapeutics, Inc.

Structures of Mouse and Human GITR-GITRL Complexes Reveal Unique TNFSF Interactions
Feng Wang, PhD, Associate Director, Recombinant Proteins, Bristol-Myers Squibb

The Temporal Dynamics of the Humoral Immune Response Following COVID-19 Recovery and Immunisation with mRNA Vaccine
Yariv Wine, PhD, Assistant Professor, The Shmunis School of Biomedicine and Cancer Research, Tel Aviv University

Native SEC-MS for Characterizing Therapeutic Monoclonal Antibodies: A Glimpse in the Formation Mechanism of Antibody Aggregates
Jing Xu, PhD, Scientist I, Analytical Chemistry, Biogen

Engineering Cis-Targeted Immunomodulators to Enhance Their Selectivity and Effectiveness as Therapeutics
Yik Andy Yeung, PhD, CTO, Asher Biotherapeutics

Targeting B Cell Malignancies with Multi-Specific Cytotoxic CD4+ T Cells
Baochun Zhang, PhD, Assistant Professor, Medical Oncology, Dana Farber Cancer Institute

Efficient NK Cell Redirection byTargeting NKp30
Stefan Zielonka, PhD, Associate Director, Protein Engineering & Antibody Technologies, Merck KGaA

* As of 28 July. Please see individual agenda pages for most current speaker information.